Patents Assigned to Apotex, Inc.
  • Patent number: 10723739
    Abstract: The present invention provides processes for the preparation of Ribociclib, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the preparation of a compound of Formula (4), and its conversion to Ribociclib (1).
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: July 28, 2020
    Assignee: Apotex Inc.
    Inventors: Daoke Dou, Kangying Li, Fuchang Zhang, Jiang Pei, Wancheng Guo
  • Patent number: 10662178
    Abstract: The present invention provides a novel crystalline form of Olaparib comprising Olaparib and benzyl alcohol, compositions thereof, and the use of this crystalline form in the treatment of cancers, such as germline BRCA-mutated (gBRCAm) advanced ovarian cancer.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: May 26, 2020
    Assignee: Apotex Inc.
    Inventors: Allan W. Rey, Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili
  • Patent number: 10632107
    Abstract: The present invention provides crystalline forms of Deutetrabenazine. Specific crystalline forms provided by the present invention include Deutetrabenazine Form APO-I, a co-crystal of Deutetrabenazine and quercetin, and Deutetrabenazine Form APO-II, a co-crystal of Deutetrabenazine and luteolin. Also provided are pharmaceutical compositions including the Deutetrabenazine crystalline forms, and the use of these forms in the treatment of tardive dyskinesia and chorea associated with Huntington's disease.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 28, 2020
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Allan W. Rey
  • Patent number: 10611772
    Abstract: The present invention provides a novel crystalline form of Ribociclib succinate, Ribociclib succinate Form APO-I, including Ribociclib succinate, benzyl alcohol and water, compositions thereof, processes for the preparation thereof, and the use of this crystalline form in the treatment of conditions associated with increased CDK4/6 kinase activity, and in particular, cancers, including certain forms of breast cancer.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: April 7, 2020
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili
  • Patent number: 10556887
    Abstract: The present invention provides processes for the preparation of Veliparib (1), as well as intermediates useful in the preparation thereof. In particular, processes are provided for the production of the compound of Formula (3), or a salt thereof, and cyclization to afford Veliparib (1).
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: February 11, 2020
    Assignee: Apotex Inc.
    Inventors: Prabhudas Bodhuri, Kaarina K. Milnes, Melanie R. A. Green, Gamini Weeratunga, Boris Gorin
  • Patent number: 10513504
    Abstract: The present invention provides processes for the preparation of Apalutamide (1), as well as intermediates useful in the preparation thereof. In particular, the process of the invention utilizes the intermediate compound of Formula (2), wherein G is OH or a leaving group, which provides improvements over the known processes for the preparation of Apalutamide (1).
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: December 24, 2019
    Assignee: Apotex Inc.
    Inventors: Prabhudas Bodhuri, Alfredo Paul Ceccarelli, Michael R. Emmett, Avedis Karadeolian, Fabio E. S. Souza, Gamini Weeratunga, Boris Gorin
  • Patent number: 10513500
    Abstract: The present invention provides novel crystalline forms of Lesinurad, pharmaceutical compositions including these crystalline forms, and their use in the treatment of hyperuricemia associated with gout. Specific crystalline forms provided by the present invention include Lesinurad Forms APO-I, a hemi-methanolate, APO-II, a hemi-ethanolate, and APO-III, a co-crystal of Lesinurad and nicotinamide.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: December 24, 2019
    Assignee: Apotex Inc.
    Inventors: Jenny L. Gerster, Katherine A. Rantanen, Allan W. Rey
  • Patent number: 10487059
    Abstract: The present invention provides a novel crystalline form of Eluxadoline, Eluxadoline Form APO-I, a co-crystal of Eluxadoline and methyl nicotinate, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of opioid-modulated disorders, and in particular, gastrointestinal disorders, including irritable bowel syndrome with diarrhea (IBS-D).
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: November 26, 2019
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya
  • Patent number: 10407396
    Abstract: The present invention provides a novel crystalline form of Selexipag, Selexipag Form APO-I, which is a methanol solvate of Selexipag, compositions thereof, and the use of this crystalline form in the treatment of pulmonary arterial hypertension.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: September 10, 2019
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Annyt Bhattacharyya, Jenny L. Gerster, Allan W. Rey
  • Patent number: 10351537
    Abstract: The present invention provides processes for the preparation of Lesinurad (1), as well as intermediates useful in the preparation thereof. In particular, the processes of the invention utilize novel intermediate compounds of Formulas (3) and (11), which provide improvements over the known processes for the preparation of Lesinurad (1).
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: July 16, 2019
    Assignee: Apotex Inc.
    Inventors: Prabhudas Bodhuri, Melanie R. A. Green, Avedis Karadeolian, Gamini Weeratunga, Boris Gorin
  • Patent number: 10301322
    Abstract: The present invention provides processes for the preparation of Edoxaban (1) and salts thereof, as well as intermediates thereof. In particular, intermediate compounds and/or salts of the Formulae (3), (4), (6-A), (7-A), (8-A), (9-A) and (10-AS) are provided.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: May 28, 2019
    Assignee: Apotex Inc.
    Inventors: Prabhudas Bodhuri, Avedis Karadeolian, Eduardo Gustavo Cammisa, Stuart P. Green, Melanie R. A. Green, Alfredo Paul Ceccarelli
  • Publication number: 20190023758
    Abstract: A method for purifying rHuEPO through the use of a multi-step filtration process which provides for a rHuEPO product having superior stability and shelf-life.
    Type: Application
    Filed: August 2, 2018
    Publication date: January 24, 2019
    Applicant: Apotex Inc.
    Inventors: Jason Everett Dowd, Robert Weik, Thomas Hemetsberger
  • Patent number: 10183024
    Abstract: The present invention provides crystalline forms of Ibrutinib. Specific crystalline forms provided by the present invention include Ibrutinib Form APO-I, an anhydrous form; APO-II, a methyl benzoate solvate of Ibrutinib; and APO-IV, a methyl salicylate solvate of Ibrutinib.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: January 22, 2019
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili, Allan W. Rey, Boris Gorin
  • Patent number: 10066001
    Abstract: A method for purifying rHuEPO through the use of a multi-step filtration process which provides for a rHuEPO product having superior stability and shelf-life.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 4, 2018
    Assignee: Apotex Inc.
    Inventors: Jason Everett Dowd, Robert Weik, Thomas Hemetsberger
  • Patent number: 10016423
    Abstract: A solid form of Nilotinib hydrochloride, which exists as a co-crystal of nilotinib hydrochloride and levulinic acid having a molar ratio of nilotinib hydrochloride to levulinic acid of 1:2, and a process for the preparation of the co-crystal.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: July 10, 2018
    Assignee: Apotex Inc.
    Inventors: Matthew Pompili, David A. Stradiotto, Probal Kanti Datta
  • Patent number: 9994523
    Abstract: The invention relates to organic salts of Saxagliptin and processes for their preparation.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: June 12, 2018
    Assignee: Apotex Inc.
    Inventors: Padiyath Mohammed Akbarali, Venkata Ramana Kintali, Shreenivasa Murthy H N, Prakash Bhaskar Shetty, Narendra Manjeshwar Mallya, Venkataramana Lachhi Reddy
  • Patent number: 9944616
    Abstract: The present invention provides processes for the preparation of Tasimelteon (1), as well as processes for the preparation of intermediates of Formulas (2), (3) and (4) useful in the preparation of Tasimelteon (1).
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: April 17, 2018
    Assignee: Apotex Inc.
    Inventors: Yajun Zhao, Murali Kondamreddy, Peter Garth Blazecka, Gamini Weeratunga, Craig Stewart, Nalini Nagireddy, Michael B. Johansen, Uma Kotipalli
  • Patent number: 9938240
    Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: April 10, 2018
    Assignee: Apotex Inc.
    Inventors: Tim Fat Tam, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Tao Xin, Birenkumar Shah
  • Patent number: 9809551
    Abstract: Provided herein is a polymorphic form of Ivacaftor, namely APO-I, as well as processes for the preparation and pharmaceutical compositions of the same. Also, provided is a new solvate of Ivacaftor, processes for its preparation and use in the preparation of pure Ivacaftor.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: November 7, 2017
    Assignee: Apotex Inc.
    Inventors: Padiyath Mohammed Akbarali, Kintali Venkata Ramana, Heggadde Nanjunda Bhatta Shreenivasa Murthy, Sankaran Suresh Kumar, Ekkaluru Vijaya Bhaskar, Nechipadappu Sunil Kumar, Karad Manjunath
  • Patent number: 9776970
    Abstract: The present subject matter relates to solvates and the amorphous form of bosutinib; the solvates namely being a propylene glycol solvate and an acetonitrile solvate. Also provided are processes for preparing the propylene glycol solvate, the amorphous form and the crystalline acetonitrile solvate of bosutinib; as well as compositions comprising said forms. Bosutinib is a 3-quinolinecarbonitrile kinase inhibitor and is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CMS) with resistance or intolerance to prior therapy.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: October 3, 2017
    Assignee: Apotex Inc.
    Inventors: Padiyath Mohammed Akbarali, Venkata Ramana Kintali, Heggadde Nanjunda Bhatta Shreenivasa Murthy, Girisha Meenkere, Somanath Bhupal Venkata, Raja Ramesh Manda, Vishal Amrutlal Sodha, Abbulu Kante